- Conditions
- Depressive Disorder, Major, Inflammation
- Interventions
- Infliximab, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 25 Years to 50 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 159
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ulcerative Colitis
- Interventions
- Ozanimod, Conventional therapy, Advanced therapy
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 2,828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Eden Prairie, Minnesota
- Conditions
- Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 35 Years to 49 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Individualized Dosage Precision IFX Dashboard
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 6 Years to 45 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Graft vs Host Disease
- Interventions
- Infliximab
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2006
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Crohn's Disease
- Interventions
- Remicade
- Drug
- Lead sponsor
- Shradha Agarwal
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Inflammatory Bone Disease
- Interventions
- Infliximab Assay
- Diagnostic Test
- Lead sponsor
- Cares, Kristen, M.D.
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Crohn Disease
- Interventions
- RoadMAB precision dashboard, Infliximab precision dosing
- Device · Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years to 22 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- No Intervention
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 6 Years to 23 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Crohn Disease
- Interventions
- Infliximab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 120 participants
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Arthritis, Rheumatoid
- Interventions
- ABP 710, Infliximab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 23 more
- Conditions
- Depression
- Interventions
- Infliximab, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Mucocutaneous Lymph Node Syndrome
- Interventions
- IVIG, Infliximab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more
- Conditions
- Graft-Versus-Host Disease
- Interventions
- Infliximab
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Uveitic Macular Edema, Intraocular Inflammation
- Interventions
- Infliximab (intravitreal, 2.0mg/0.05ml)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kawasaki Disease
- Interventions
- Infliximab (Remicade), Intravenous immunoglobulin (IVIG)
- Drug · Biological
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Crohn's Disease, Protein Metabolism, Energy Metabolism
- Interventions
- Stable isotope infusions
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Kawasaki Disease
- Interventions
- Infliximab, Placebo
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 4 Weeks to 17 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- La Jolla, California • Columbus, Ohio
- Conditions
- Crohn's Disease
- Interventions
- adalimumab
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 74 more
- Conditions
- Healthy Volunteer
- Interventions
- MT-201
- Drug
- Lead sponsor
- Mirador Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Juvenile Rheumatoid Arthritis
- Interventions
- Infliximab
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
- Drug
- Lead sponsor
- Dr. Larry W. Moreland
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sarcoidosis
- Interventions
- Cytotoxic drug
- Other
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 15 Years to 90 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio